Cover Image
市場調查報告書

美國的血糖檢驗市場

U.S. Glucose Testing Markets

出版商 TriMark Publications 商品編碼 243429
出版日期 內容資訊 英文 280 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的血糖檢驗市場 U.S. Glucose Testing Markets
出版日期: 2015年09月01日 內容資訊: 英文 280 Pages
簡介

美國的血糖檢驗,由於新的分析技術和糖尿病治療發展而劇烈變化。體外診斷產業的血糖檢驗領域變成熟,不過,糖尿病管理的家庭檢驗設備和POC等幾個領域,預計達成高成長。

本報告以美國市場的血糖檢驗和糖尿病管理領域為焦點,提供目前血清、血小板、全血糖濃度檢測方法、檢測設備、試劑等概說,為您概述為以下內容。

第1章 概要

第2章 糖尿病

  • 美國的糖尿病人口統計
  • 糖尿病相關的代謝性疾病
    • 前糖尿病症候群
    • 代謝症候群
    • 糖尿病的進展
    • 糖尿病和炎症
    • 風險因素和糖尿病
    • 糖尿病的併發症和共存症
  • 糖尿病的經濟學

第3章 市場分析:規模、成長、佔有率、競爭企業

  • 美國市場
  • 競爭趨勢
  • 推動市場因素和阻礙因素
  • 市場與產品趨勢
  • 策略性建議
  • 競爭策略
  • 血糖儀的新市場機會
  • 鄰近市場

第4章 血糖診斷與監測相關建議

  • 糖尿病的診斷
  • 糖尿病治療的嚴苛的血糖控制
  • 對糖尿病的血糖控制的建議
  • 低血糖和治療

第5章 血糖檢驗技術平台與消耗產品

  • 血糖定量技術類型
  • 血糖濃度檢測所採用的酵素反應
  • 血糖監測儀的開發:歷史評價
  • 血糖儀的準確度
  • 血糖檢查裝置主要課題
  • 現有的血糖檢驗的限制
  • 血糖儀性能的潛在改良領域
  • 血糖試劑試紙
  • 手持血糖儀和臨床試驗所用血糖檢測的比較
  • 持續血糖監測系統技術
  • 非侵入性血糖監測系統技術摘要
  • A1c監測技術
  • 果糖胺測試
  • 相關試劑與設備

第6章 市場上的血糖檢查裝置

  • 手持血糖儀和自我檢驗用帶
  • 專業手持血糖儀
  • 臨床血液化學分析設備
  • 持續病患監測系統
  • 非侵入性血糖監測系統
  • A1c檢驗
  • 新產品的上市
  • 開發中的新血糖儀資料與管理軟體
  • 近幾年的產業活動
  • M&A活動

第7章 血糖檢驗的商務趨勢

  • 臨床性血糖檢驗的促進要素
  • 以POC血糖檢驗為中心的競爭
  • 醫療費管理
  • 患者經營管理的變化
  • 實驗室照護的區域化
  • 衛星設施
  • 就地檢驗 其他

第8章 技術趨勢

  • 目前OTC血糖儀的改良
  • 生物感應器技術
  • 果糖胺測試
  • 人工胰臟
  • 遠程醫療設備
  • 非傳統樣品採取方法
  • 資料管理

第9章 企業簡介

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: TMRUSGT15-0901

U.S. glucose testing is undergoing a significant transition, driven by new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, several segments of the market, such as home testing devices for diabetes management and point of care (POC) instruments for use in professional settings, will exhibit strong growth. Direct access testing has emerged as a strong force in the blood glucose testing segment, and non-invasive and minimally-invasive testing now represent major new areas for the application of IVD testing. This TriMark Publications report describes the specific market segments for blood glucose testing and diabetes management in the U.S. market. It reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum, plasma or whole-blood glucose concentrations. Additionally, this study examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctors offices and at-home care locations. Moreover, it analyzes almost all of the companies known to be marketing, manufacturing or developing glucose testing products for the U.S. market. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included.

Table of Contents

1. Overview

  • 1.1. Statement of Report
  • 1.2. About This Report
  • 1.3. Scope of the Report
  • 1.4. Methodology
  • 1.5. Executive Summary

2. Diabetes

  • 2.1. Demographics of Diabetes in the U.S.
  • 2.2. Understanding the Metabolic Conditions Underlying and Associated with Diabetes
    • 2.2.1. Pre-Diabetes Syndrome
    • 2.2.2. Metabolic Syndrome
    • 2.2.3. Progression of Diabetes
    • 2.2.4. Diabetes and Inflammation
    • 2.2.5. Risk Factors and Diabetes
      • 2.2.5.1. Obesity
      • 2.2.5.2. Stress-Induced Hyperglycemia
    • 2.2.6. Complications and Co-Morbidities in Diabetes
      • 2.2.6.1. Preventing Complications and Co-Morbidities in Diabetes
      • 2.2.6.2. Cardiovascular Disease Facts
  • 2.3. Economics of Diabetes

3. Market Analysis: Size, Growth, Share and Competitors

  • 3.1. U.S. Market
    • 3.1.1. U.S. Over-the-Counter (OTC) Self-Testing Glucose Market
    • 3.1.2. U.S. Professional Glucose Testing Market
    • 3.1.3. Continuous Glucose Monitoring Markets
  • 3.2. Competitive Situation
    • 3.2.1. Key Players
    • 3.2.2. Analyses of the Self-Testing Market Conditions, Competition and Product Mix
    • 3.2.3. Analyses of the Professional Blood Glucose Monitoring Market
  • 3.3. Market Drivers and Restraints
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
  • 3.4. Market and Product Trends
    • 3.4.1. Market Trends
    • 3.4.2. Technology Trends
  • 3.5. Strategic Recommendations
  • 3.6. Competitive Strategies
  • 3.7. New Opportunities in the Professional Blood Glucose Meter Market
  • 3.8. Adjacent Markets

4. Glucose Diagnostic and Monitoring Recommendations

  • 4.1. Diagnosis of Diabetes Mellitus
  • 4.2. Tight Glucose Control in Treating Diabetes
    • 4.2.1. Tight Glucose Control Lowers Cardiovascular Complications
  • 4.3. Recommendations for Glucose Control in Diabetics
    • 4.3.1. New Plasma Blood Sugar and HbA1c Target Recommendation for Children with Type 1 Diabetes
    • 4.3.2. Recommended Frequency of Blood Glucose Self-Testing
    • 4.3.3. Using Blood Glucose Data to Monitor and Modify Patient Therapy
    • 4.3.4. Testing in Individuals with Type 2 Diabetes
    • 4.3.5. Continuous Glucose Monitoring (CGM)
    • 4.3.6. A1c Testing Recommendations
    • 4.3.7. Recommendations for Diabetes Care and Glucose Testing in the Hospital Setting
  • 4.4. Hypoglycemia and Treatment

5. Glucose Testing Technology Platforms and Consumable Products

  • 5.1. Types of Glucose Determination Technologies
  • 5.2. Enzymatic Reactions Used to Determine Glucose Concentrations
    • 5.2.1. Glucose Oxidase (GOX)
    • 5.2.2. Glucose Dehydrogenase (GDH)
      • 5.2.2.1. GDH-NAD (Glucose Dehydrogenase-Nicotinamide Adenine Dinucleotide)
      • 5.2.2.2. GDH-FAD (Glucose Dehydrogenase-Flavin Adenine Dinucleotide)
      • 5.2.2.3. GDH-PQQ (Glucose Dehydrogenase-Pyrroloquinoline Quinone)
    • 5.2.3. Glucose Hexokinase
  • 5.3. Development of Blood Glucose Monitors: A Historical Evaluation
    • 5.3.1. First-Generation Blood Glucose Biosensors
    • 5.3.2. Second-Generation Blood Glucose Biosensors
    • 5.3.3. Third-Generation Blood Glucose Biosensor
  • 5.4. Accuracy and Precision in Glucose Meters
    • 5.4.1. Clinical and Laboratory Standards Institute (CLSI) POCT12-A3
    • 5.4.2. International Organization for Standardization (ISO) 15197:2013
    • 5.4.3. FDA Guidelines for Blood Glucose Testing Systems
    • 5.4.4. Determining Clinical Accuracy Using the Error Grid Analysis (EGA)
    • 5.4.5. Quality Control Criteria
    • 5.4.6. Potential Variables Affecting Glucose Concentrations
  • 5.5. Key Issues for Glucose Testing Devices
    • 5.5.1. Important Elements for Glucose Testing
    • 5.5.2. Key Features to Aid Specific Patient Populations
  • 5.6. Limitations of Existing Glucose Testing
    • 5.6.1. Common User Errors in Glucose Self-Testing
    • 5.6.2. Interfering Substances and Conditions
      • 5.6.2.1. Environmental
      • 5.6.2.2. Physiologic
      • 5.6.2.3. Operational
      • 5.6.2.4. Manufacturing Variations
      • 5.6.2.5. Drugs/Medications
      • 5.6.2.6. Patient Factors
    • 5.6.3. Errors Associated with GDH-PQQ Technology
    • 5.6.4. Optimizing of Point of Care (POC) Blood Glucose Testing
  • 5.7. Potential Areas of Improvement in Blood Glucose Meter Performance
    • 5.7.1. Off-Label/Modified Use of Waived Blood Glucose Monitoring Systems
  • 5.8. Blood Glucose Reagent Test Strips
  • 5.9. Comparison of Hand-Held Blood Glucose Meters with Clinical Laboratory Glucose Measurements
  • 5.10. Continuous Glucose Monitoring Technology
    • 5.10.1. Advantages of Continuous Readings
    • 5.10.2. FDA Approval of CGM
    • 5.10.3. CGM Functions to Consider
    • 5.10.4. New Technologies for CGM
  • 5.11. Summary of Technologies Being Explored for Non-Invasive Glucose Monitoring
    • 5.11.1. GlucoTrack
    • 5.11.2. Non-Invasive Glucose Monitoring Technologies in Development
    • 5.11.3. Goals of Non-Invasive Testing
    • 5.11.4. Non-Invasive Diabetes Screening Test
  • 5.12. A1c Monitoring Technology
    • 5.12.1. PTS Diagnostics' (Chek Diagnostics') A1c Home Test
  • 5.13. Fructosamine Test
  • 5.14. Related Reagents and Equipment
    • 5.14.1. Lancets
      • 5.14.1.1. Types of Lancing Devices
      • 5.14.1.2. Market Size
    • 5.14.2. Control Solutions and Calibrators
    • 5.14.3. Sharps Devices
    • 5.14.4. Needle Destruction Devices
    • 5.14.5. Urine Strips
    • 5.14.6. Ketone Testing
    • 5.14.7. Long-Term Glucose Sensing Bio-Implants

6. Glucose Testing Devices on the Market

  • 6.1. Hand-held Blood Glucose Meters and Strips for Self-Testing
    • 6.1.1. LifeScan, Inc.
    • 6.1.2. Roche Diagnostics Corporation
    • 6.1.3. Bayer
    • 6.1.4. Abbott
    • 6.1.5. Agamatrix, Inc.
    • 6.1.6. Arkray, Inc.
    • 6.1.7. Bionime Corporation
    • 6.1.8. BioSense Medical Devices
    • 6.1.9. CVS/Pharmacy
    • 6.1.10. Diabetic Supply of Suncoast
    • 6.1.11. Entra Health Systems
    • 6.1.12. Fifty50 Pharmacy
    • 6.1.13. Fora Care
    • 6.1.14. Genesis Health Technologies
    • 6.1.15. GlucoCom
    • 6.1.16. iHealth
    • 6.1.17. Infopia
    • 6.1.18. Livongo Health
    • 6.1.19. Nipro Diagnostics, Inc.
    • 6.1.20. Nova Biomedical
    • 6.1.21. Oak Tree International Holdings, Inc.
    • 6.1.22. Omnis Health
    • 6.1.23. Phylosis
    • 6.1.24. Prodigy Diabetes Care, LLC (an affiliate of Diagnostic Devices, Inc.)
    • 6.1.25. Sanofi
    • 6.1.26. Target
    • 6.1.27. Telcare
    • 6.1.28. Tyson Biomedical
    • 6.1.29. US Diagnostics
    • 6.1.30. Walgreens
    • 6.1.31. Walmart
    • 6.1.32. 77 Elektronika Kft.
    • 6.1.33. A. Menarini Diagnostics
    • 6.1.34. All Medicus
    • 6.1.35. i-SENS
    • 6.1.36. Apex Biotechnology Corp.
    • 6.1.37. Glucoplus, Inc.
    • 6.1.38. Polymer Technology Systems
    • 6.1.39. Smiths Medical MD, Inc.
    • 6.1.40. TaiDoc Technology Corp.
    • 6.1.41. IN4 Technology Corporation
    • 6.1.42. ACON Laboratories, Inc.
    • 6.1.43. Pepex Biomedical
    • 6.1.44. HMD BioMedical
    • 6.1.45. BTNX, Inc.
    • 6.1.46. Shasta Technologies and Decision Diagnostics Corporation
  • 6.2. Hand-held Blood Glucose Meters for Professional Use
    • 6.2.1. Abbott
      • 6.2.1.1. Precision Xceed Pro Blood Glucose and Beta-Ketone Monitoring System
      • 6.2.1.2. i-STAT System
    • 6.2.2. ACON Laboratories
      • 6.2.2.1. On Call Platinum Blood Glucose Monitoring System
    • 6.2.3. Alere
      • 6.2.3.1. epoc Blood Analysis System
      • 6.2.3.2. Alere Cholestech LDX System
    • 6.2.4. Apex Biotechnology
    • 6.2.5. ARKRAY, Inc.
      • 6.2.5.1. Assure Platinum and Assure Prism Multi
    • 6.2.6. EKF Diagnostics
      • 6.2.6.1. Biosen Series of Glucose and Lactate Analyzers
    • 6.2.7. Fora Care
      • 6.2.7.1. VSM100 Pro Vital Sign Monitor
    • 6.2.8. HemoCue (part of Radiometer)
      • 6.2.8.1. HemoCueÒ Glucose 201+, Glucose 201 RT, Glucose 201 DM, and Glucose DM RT Systems
    • 6.2.9. HMD BioMedical
      • 6.2.9.1. NS100
    • 6.2.10. Infopia
      • 6.2.10.1. Lipid Pro
    • 6.2.11. Jant Pharmacal
      • 6.2.11.1. LipidPlus® Lipid Profile and Glucose Measuring System
    • 6.2.12. Medtronic
      • 6.2.12.1. iPro Continuous Glucose Monitor
    • 6.2.13. Nova Biomedical
      • 6.2.13.1. StatStrip Hospital Glucose Monitoring System
    • 6.2.14. Polymer Technology Systems, Inc.
      • 6.2.14.1. CardioChek PA Point of Care Device
    • 6.2.15. Roche
      • 6.2.15.1. Accu-Chek Inform II System
      • 6.2.15.2. Accutrend Plus System
    • 6.2.16. Techno Medica Co., Ltd.
      • 6.2.16.1. GASTAT-mini
    • 6.2.17. LifeScan
  • 6.3. Clinical Blood Chemistry Analyzers
    • 6.3.1. Abaxis, Inc.
      • 6.3.1.1. Piccolo® Xpress Blood Chemistry Analyzers
    • 6.3.2. Abbott
      • 6.3.2.1. ARCHITECT
    • 6.3.3. Alere
      • 6.3.3.1. Cholestech LDX® System
    • 6.3.4. AMS
      • 6.3.4.1. SAT 600
      • 6.3.4.2. SAT 450
      • 6.3.4.3. LIASYS
      • 6.3.4.4. ELLIPSE
      • 6.3.4.5. NEPHYS
      • 6.3.4.6. VEGASYS
    • 6.3.5. ARKRAY, Inc.
      • 6.3.5.1. SPOTCHEM™ EZ
      • 6.3.5.2. SPOTCHEM D-02 (SD-4810) & SPOTCHEM D-03(SD-4820)
    • 6.3.6. Beckman Coulter
      • 6.3.6.1. AU chemistry systems
      • 6.3.6.2. UniCel® DxC chemistry systems
    • 6.3.7. DiaSys
      • 6.3.7.1. InnovaStar®
      • 6.3.7.2. SensoStar GL30 touch and SensoStar GLHsix
      • 6.3.7.3. respons® 910 and 920
      • 6.3.7.4. BioMajesty® JCA-BM6010/C
    • 6.3.8. Diatron
      • 6.3.8.1. Pictus 500
      • 6.3.8.2. Pictus 700
      • 6.3.8.3. Pictus 400
      • 6.3.8.4. Pictus 200
      • 6.3.8.5. Pictus B
    • 6.3.9. Instrumentation Laboratory
      • 6.3.9.1. IL GEM Premier 4000, 3500 and 3000
    • 6.3.10. LifeHealth (formerly International Techidyne Corporation)
      • 6.3.10.1. IRMA TruPoint®
    • 6.3.11. Nova Biomedical
      • 6.3.11.1. Nova Electrolyte/Chemistry Analyzers
      • 6.3.11.2. Stat Profile® Critical Care Xpress
      • 6.3.11.3. Stat Profile® pHOx® Plus
      • 6.3.11.4. Stat Profile® pHOx® Ultra
    • 6.3.12. Radiometer™
      • 6.3.12.1. ABL™80 FLEX
      • 6.3.12.2. ABL™90 FLEX
      • 6.3.12.3. ABL™800 FLEX
    • 6.3.13. Randox Laboratories
      • 6.3.13.1. RX Series of clinical chemistry analyzers
    • 6.3.14. Roche
      • 6.3.14.1. cobas® 4000, cobas® 6000, and cobas® 8000 modular Analyzer Series
      • 6.3.14.2. cobas® c 111 Analyzer
      • 6.3.14.3. cobas® b 221 System
      • 6.3.14.4. Reflotron® Systems
    • 6.3.15. Siemens Healthcare Diagnostics
      • 6.3.15.1. Point-of-care Blood Gas Analyzers
      • 6.3.15.2. Central (Core) Laboratory Clinical Chemistry Systems
    • 6.3.16. Span Diagnostics
      • 6.3.16.1. Autochem Xact
      • 6.3.16.2. BT 1500
    • 6.3.17. Stanbio Laboratory
      • 6.3.17.1. Excel Semi-Automated Clinical Chemistry Analyzer
      • 6.3.17.2. Sirrus® Clinical Chemistry Analyzer
    • 6.3.18. Techno Medica Co., Ltd
    • 6.3.19. Thermo Fisher Scientific
      • 6.3.19.1. Indiko™ Clinical and Specialty Chemistry System
      • 6.3.19.2. Indiko™ Plus Clinical and Specialty Chemistry System
      • 6.3.19.3. Konelab™ 20XT Clinical Chemistry Analyzer
      • 6.3.19.4. Konelab™ PRIME 60 Clinical Chemistry Analyzer
      • 6.3.19.5. MGC 240 Benchtop Analyzer
    • 6.3.20. Tokyo Boeki Medisys
      • 6.3.20.1. BiOLis family of analyzers
    • 6.3.21. YSI Life Sciences
      • 6.3.21.1. YSI 2300 STAT Plus™ Glucose & Lactate Analyzer
  • 6.4. Continuous Glucose Patient Monitoring Systems
    • 6.4.1. Medtronic's Continuous Glucose Monitoring Systems (CGMS)
      • 6.4.1.1. MiniMed Paradigm REAL-Time Revel System
      • 6.4.1.2. Guardian REAL-Time
      • 6.4.1.3. MiniMed 530G with Enlite
      • 6.4.1.4. iPro®2 Professional CGM
    • 6.4.2. Dexcom, Inc.'s Continuous Glucose Monitoring System
      • 6.4.2.1. G4. Platinum Continuous Glucose Monitoring System
      • 6.4.2.2. Dexcom G4 Platinum Continuous Glucose Monitoring System with Share
      • 6.4.2.3. Dexcom G5 Mobile Continuous Glucose Monitoring System
    • 6.4.3. Animas Vibe System
    • 6.4.4. Abbott's Continuous Glucose Monitor System
      • 6.4.4.1. FreeStyle Libre
      • 6.4.4.2. FreeStyle Navigator (discontinued)
    • 6.4.5. GlucoDay® S Continuous Glucose Monitor
    • 6.4.6. Minimally-Invasive Continuous Glucose Monitors in Development
      • 6.4.6.1. GlySens Inc.
      • 6.4.6.2. Senseonics (formerly Sensors for Medicine and Science)
      • 6.4.6.3. Ultradian
  • 6.5. Non-Invasive Glucose Patient Monitoring Systems
    • 6.5.1. Cygnus GlucoWatch Biographer
    • 6.5.2. AiMedics
    • 6.5.3. Echo Therapeutics
    • 6.5.4. EyeSense GmbH
    • 6.5.5. Freedom Meditech
    • 6.5.6. Google and Novartis
    • 6.5.7. Integrity Applications Ltd.
    • 6.5.8. Lein Applied Diagnostics
    • 6.5.9. LighTouch Medical
    • 6.5.10. Miraculins, Inc.
    • 6.5.11. Xhale Inc.
  • 6.6. A1c Testing
  • 6.7. New Product Launches
    • 6.7.1. OneTouch Verio Sync Blood Glucose Monitoring System
    • 6.7.2. Medtronic's MiniMed 530G with Enlite Sensor Technology
    • 6.7.3. Contour Next Link Meter Approved for Use with Medtronic's New MiniMed 530G with Enlite Insulin Pump System
    • 6.7.4. Abbott Receives CE Mark for FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System
    • 6.7.5. Abbott Receives FDA Clearance for FreeStyle Precision Pro Blood Glucose and β-Ketone Monitoring System
    • 6.7.6. LabStyle Innovations' Dario Diabetes Management System
    • 6.7.7. BlueStar by WellDoc
    • 6.7.8. FDA Approves Bayer's Contour Next EZ
    • 6.7.9. Glooko Received its Second 510(k) Clearance for Glucose Monitoring Logbook App
    • 6.7.10. Sanofi-Aventis's iBGStar
    • 6.7.11. iHealth Glucose Meter Device
    • 6.7.12. MyGlucoHealth Diabetes
    • 6.7.13. Enlite™ Sensor
    • 6.7.14. Medtronic Gains Approval of First Artificial Pancreas Device System, the MiniMed® 530G with Enlite®
    • 6.7.15. Nipro Diagnostics TrueMetrix Air
    • 6.7.16. Animas Vibe System
    • 6.7.17. Abbott's FreeStyle Libre and FreeStyle Libre Pro
    • 6.7.18. Abbott's FreeStyle Precision Neo Blood Glucose Monitoring System
    • 6.7.19. Dexcom G4 Platinum Continuous Glucose Monitoring System with Share
    • 6.7.20. Medtronic's MiniMed Connect
    • 6.7.21. Dexcom G5 Mobile CGM System
  • 6.8. Blood Glucose Meters, CGMs, and Data Management Software in Development
    • 6.8.1. Abbott's Flash Glucose Monitoring System
    • 6.8.2. Google Announces Plan to Create Contact Lens Glucose Sensors
    • 6.8.3. Socrates Health Solutions' Companion Blood Glucose Monitor
    • 6.8.4. Boston University's Bionic Pancreas Project
    • 6.8.5. IGI Stat's Test to Identify Type 1 Diabetes
    • 6.8.6. Medtronic's Next-generation Combination Pump and CGM
    • 6.8.7. Medtronic and IBM's Watson Health to Develop Data Management Solutions
  • 6.9. Recent Industry Activity
    • 6.9.1. Roche Diagnostics Corp. Cutting Jobs in Diabetes Division
    • 6.9.2. AgaMatrix and Sanofi-Aventis Enter Global Diabetes Partnership
    • 6.9.3. LifeScan, Inc. Terminates Exclusive Supply Agreement with Medtronic MiniMed
    • 6.9.4. Medtronic and Bayer Healthcare Expand International Alliance
    • 6.9.5. PositiveID Corporation Licenses iglucose Technology to Smart Glucose Meter Corp
    • 6.9.6. BD and JDRF Collaborating on a Device Using a Single Infusion Catheter for Both CGM and Pump
    • 6.9.7. Court Sides with Decision Diagnostics in Patent Infringment Case
    • 6.9.8. Senseonics Partners with Rubin Medical to Commercialize New CGM
    • 6.9.9. Abbott re-entering Continuous Glucose Monitoring Market in Europe with FreeStyle Libre
    • 6.9.10. Medtronic and IBM's Watson Health Partnering to Develop Personalized Diabetes Management Solutions
  • 6.10. M&A Activity
    • 6.10.1. Home Diagnostics, Inc. and Nipro Diabetes Systems, Inc. Merge to Become Nipro Diagnostics, Inc.
    • 6.10.2. Medtronic, Inc. (MDT) Acquires New Diabetes Technology from PreciSense AS
    • 6.10.3. Geonostics Acquires FlexSite's Consumer Diabetes Tests
    • 6.10.4. Radiometer Medical Acquires Hemocue
    • 6.10.5. Additional M&A
    • 6.10.6. Important Deals in BGM market

7. Business Trends in Glucose Testing

  • 7.1. Drivers of Clinical Glucose Testing
  • 7.2. Competition for Professional POC Glucose Testing
  • 7.3. Healthcare Cost Controls
  • 7.4. Changes in Patient Management
  • 7.5. Regionalization of Laboratory Care
  • 7.6. Satellite Facilities
  • 7.7. Professional Point of Care Testing
  • 7.8. Factors Affecting OTC Medical Product Distribution
  • 7.9. Drug Stores Critical to the Diabetic Care Category
  • 7.10. Drivers of OTC and Self-Testing Markets
    • 7.10.1. Brand Loyalty
  • 7.11. Cost Elements of Glucose Self-Testing
  • 7.12. Blood Glucose Self-Testing Insurance Coverage and Reimbursement
  • 7.13. Reimbursement Challenges
    • 7.13.1. New Medicare Part B
  • 7.14. Managed Care
  • 7.15. Government Regulation of Medical Devices
  • 7.16. Clinical Laboratory Improvement Act (CLIA)
    • 7.16.1. Off-Label/Modified Use of Waived Blood Glucose Monitoring Systems
  • 7.17. FDA Labeling Requirements
  • 7.18. Legal Liability for Glucose Meters
  • 7.19. FDA's Artificial Pancreas Guidance Document

8. Technology Trends

  • 8.1. Improving Today's OTC Blood Glucose Meters
  • 8.2. Biosensor Technology
  • 8.3. Fructosamine Test
  • 8.4. Artificial Pancreas
  • 8.5. Telemedicine Devices
    • 8.5.1. Remote Patient Monitoring
      • 8.5.1.1. Infopia Eocene System
      • 8.5.1.2. Health Buddy Systems Monitoring Technologies
      • 8.5.1.3. GlucoCom Glucose Monitoring System
      • 8.5.1.4. Alere's DayLink Monitor
      • 8.5.1.5. Alere HomeLink Receives FDA Approval for Over-the-Counter Use
      • 8.5.1.6. iGlucose System
  • 8.6. Non-Traditional Methods for Sample Collection
  • 8.7. Data Management
    • 8.7.1. Medical Device Radiocommunications Service (MedRadio)
    • 8.7.2. Connectivity
    • 8.7.3. Advantages of Connectivity
    • 8.7.4. Connectivity Platforms
    • 8.6.5. DataLink Data Management System
    • 8.7.6. RALS-Plus
    • 8.7.7. FDA Required Software Verification
    • 8.7.8. Information Management Advances
    • 8.7.9. POL Laboratory Data Management
      • 8.7.9.1. Electronic Medical Record Systems and Physician Office Laboratory Data Linking Software
      • 8.7.9.2. Physician Office Laboratory Data Linking Software and Interface to the Laboratory Information System
      • 8.7.9.3. Technical Problems of Connectivity
      • 8.7.9.4. Web-Based Data Interface
    • 8.7.10. HIT Competition

9. Company Profiles

  • 9.1. Abaxis, Inc.
  • 9.2. Abbott Laboratories
  • 9.3. ACON Laboratories
  • 9.4. AgaMatrix
  • 9.5. Alere, Inc.
  • 9.6. All Medicus, Co., Ltd.
  • 9.7. AMS Alliance
  • 9.8. A. Menarini Diagnostics
  • 9.9. Apex Biotechnology Corporation
  • 9.10. ARKRAY USA, Inc.
  • 9.11. Bayer AG
  • 9.12. B. Braun Melsungen
  • 9.13. Beckman Coulter
  • 9.14. Bionime
  • 9.15. Bio-Rad Laboratories, Inc.
  • 9.16. Cambridge Sensors
  • 9.17. Cardiocom
  • 9.18. DexCom
  • 9.19. Diagnostic Devices/Prodigy Diabetes Care
  • 9.20. DiaSys
  • 9.21. Diatron
  • 9.22. Echo Therapeutics, Inc.
  • 9.23. Entra Health Systems
  • 9.24. Fora Care
  • 9.25. FIFTY50 Medical, Inc.
  • 9.26. Freedom Meditech
  • 9.27. Genesis Health Technologies
  • 9.28. GenExel-Sein, Inc.
  • 9.29. GlucoPlus
  • 9.30. GlySens, Inc.
  • 9.31. GlySure Limited
  • 9.32. Grove Instruments
  • 9.33. Hainice Medical
  • 9.34. HemoCue (a Quest Diagnostics company)
  • 9.35. Home Diagnostics
  • 9.36. Infopia Co., Ltd.
  • 9.37. IN4 Technology
  • 9.38. International Techidyne Corporation (ITC)
  • 9.39. Instrumentation Laboratory Company
  • 9.40. i-Sens
  • 9.41. Jant Pharmacal
  • 9.42. Johnson & Johnson
  • 9.43. LabStyle Innovations Corporation
  • 9.44. LifeHealth, LLC
  • 9.45. Medtronic
  • 9.46. Miraculins
  • 9.47. Nipro Diagnostics
  • 9.48. Nova Biomedical
  • 9.49. Polymer Technology Systems
  • 9.50. Prodigy Diabetes Care, LLC (formerly Diagnostic Devices, Inc.)
  • 9.51. Radiometer Medical
  • 9.52. Roche Diagnostics
  • 9.53. Senseonics
  • 9.54. 77 Elektronika Kft.
  • 9.55. Siemens AG
  • 9.56. Smiths Group
  • 9.57. Stanbio Laboratory
  • 9.58. TaiDoc Technology
  • 9.59. Techno Medica Co., Ltd.
  • 9.60. Telcare
  • 9.61. Tokyo Boeki Medisys
  • 9.62. US Diagnostics
  • 9.63. Ypsomed Holding
  • 9.64. YSI Life Sciences

INDEX OF FIGURES

  • Figure 2.1: New Cases of Diabetes Diagnosed in the U.S. Adult Population by Age
  • Figure 2.2: Prevalence of Diabetes by Age in the U.S.
  • Figure 2.3: Diagnosed Diabetes by Age in the U.S.
  • Figure 2.4: Percentage of U.S. Adults Diagnosed Diabetes by State
  • Figure 2.5: Number of Deaths from Diabetes by Age in the U.S.
  • Figure 2.6: Number of Diabetes Deaths by Race and Sex in the U.S.
  • Figure 2.7: Maintenance of Normal Blood Sugar Levels
  • Figure 2.8: Prevalence of Self-Reported Obesity (BMI 330) Among U.S. Adults
  • Figure 2.9: Prevalence of Obesity (BMI ≥30) Among Adults in the U.S.
  • Figure 2.10: Trends in Obesity Among Children and Adolescents in the U.S.
  • Figure 2.11: Age-Adjusted Percentage of People with Diabetes Aged 35 Years or Older Reporting Heart Disease or Stroke, by Sex, in the U.S.
  • Figure 2.12: Percentage of Adults with Diagnosed Diabetes Reporting Any Mobility Limitation, by Age, in the U.S.
  • Figure 2.13: Number (in Millions) of Adults Aged 18 Years or Older with Diagnosed Diabetes Reporting Visual Impairment, in the U.S.
  • Figure 2.14: How Diabetes Dollars are Spent in the U.S.
  • Figure 3.1: Forecasted Test Strip Usage by Different Diabetic Populations
  • Figure 4.1: Approach to Management of Hypoglycemia
  • Figure 4.2: Glycemic Status-Ranges and Health Implications
  • Figure 5.1: EGA Zones of Clinical Accuracy
  • Figure 5.2: Single-Day Continuous Blood Glucose Data
  • Figure 5.3: Factors that may Adversely Affect Glucose Testing
  • Figure 5.4: Personal Lancet Unit Sales Market Share by Geographic Region
  • Figure 6.1: Medtronic's Threshold Suspend Feature

INDEX OF TABLES

  • Table 2.1: New Cases of Diagnosed Diabetes Among U.S. Adults Aged 20 Years or Older
  • Table 2.2: U.S. Population of Diagnosed Diabetics Aged 20-79 Years
  • Table 2.3: Percentage of U.S. Adults with Diagnosed Diabetes by State
  • Table 2.4: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S.
  • Table 2.5: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes
  • Table 2.6: Prevalence of Complications Among Patients with Diabetes
  • Table 2.7: Major Causes of End-Stage Renal Disease
  • Table 2.8: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus
  • Table 2.9: Clinical Recommendations for Adults with Diabetes
  • Table 2.10: Laboratory Assessment of Diabetic Vascular Disease
  • Table 2.11: Average Years Gained Free of Diabetes-Related Disease with Intensive Management
  • Table 2.12: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases and Stroke in the U.S.
  • Table 2.13: Cost of Diagnosed Diabetes in the U.S.
  • Table 2.14: Annual Cost of Care of United Healthcare Adult Members with Diabetes
  • Table 2.15: Healthcare Utilization by Diabetic Patients
  • Table 3.1: Comprehensive Glucose Testing Market in the U.S. (includes reagents and supplies in the Self-testing and Professional Markets)
  • Table 3.2: U.S. Blood Glucose Reagent Strip Market (includes both Self-testing and Professional Markets)
  • Table 3.3: Market for Glucose Self-Testing in the U.S. (includes Meters, Strips, and Lancets)
  • Table 3.4: Market Share of U.S. Blood Glucose Self-Testing
  • Table 3.5: U.S. OTC Glucose Self-Testing Market Repeat Retail Replacement Sales Percentages
  • Table 3.6: OTC Blood Glucose Instrument Reagents by Manufacturer Retail
  • Table 3.7: Demographic Characteristics Glucose Self-Testing Kit Buyers
  • Table 3.8: Top Brand Preferences for Glucose Self-Testing Kits
  • Table 3.9: Instances when Patients Prefer Professional's Glucose Testing
  • Table 3.10: Advantages of a Glucose Self-Testing Kit
  • Table 3.11: Disadvantages of Using a Glucose Self-Testing Kit
  • Table 3.12: Popular Shopping Destinations for Buying or Seeking Information on Glucose Self-Testing Kits
  • Table 3.13: Customer Priorities-Glucose Meter Self-Testing Market
  • Table 3.14: Market for Total Professional Glucose Testing (Central Laboratory and Hospital POC & POL)
  • Table 3.15: U.S. Revenues for Professional POC Blood Glucose Monitoring (Hospital & POL)
  • Table 3.16: U.S. Continuous Glucose Monitoring Market
  • Table 3.17: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats of the Glucose Point of Care Market
  • Table 3.18: Key Market Drivers for Glucose Testing
  • Table 3.19: Point of Care Glucose Testing Market: Market Drivers Ranked in Order of Impact
  • Table 3.20: Market Drivers for Continuous Glucose Monitoring
  • Table 3.21: Key Market Restraints for Glucose Testing
  • Table 3.22: Market Restraints for Continuous Glucose Monitoring
  • Table 3.23: Point of Care Glucose Testing Market: Market Restraints Ranked in Order of Impact
  • Table 4.1: Criteria for the Diagnosis of Diabetes
  • Table 4.2: Categories of Increased Risk for Diabetes (Pre-Diabetes)
  • Table 4.3: Normal Glucose Values-Fasting State
  • Table 4.4: Criteria for Testing for Diabetes in Asymptomatic Adults
  • Table 4.5: Criteria for Type 2 Diabetes in Asymptomatic Children
  • Table 4.6: Screening for and Diagnosis of Gestational Diabetes Mellitus (GDM)
  • Table 4.7: Glycemic Recommendations for Non-Pregnant Adults with Diabetes
  • Table 4.8: Glycemic Recommendations for Women with Gestational Diabetes
  • Table 4.9: Glycemic Recommendations for Pregnant Women with Pre-Existing Diabetes
  • Table 4.10: Plasma Blood Glucose and A1c Goals for Type 1 Diabetes by Age-group
  • Table 4.11: Glucose Monitoring Recommendations
  • Table 4.12: Key Issues for SMBG in Insulin-Independent Type 2 Diabetics
  • Table 4.13: A1c Testing Recommendations
  • Table 4.14: Correlation of A1c with Mean Blood Glucose
  • Table 4.15: Glucose Monitoring Recommendations for Hospital Settings
  • Table 4.16: Glycemic Goals for Hospital Patients
  • Table 5.1: Analytic Performance Criteria for Glucose Meters
  • Table 5.2: Potential Variables Affecting Glucose Concentrations
  • Table 5.3: Key Features Considered for Glucose Testing Devices
  • Table 5.4: Common User Errors Made While Self-Testing for Blood Glucose
  • Table 5.5: Compatibility of Various Blood Glucose Meters with Icodextrin PD Solution
  • Table 5.6: Ten Factors Needed to Improve the Performance of Blood Glucose Meters
  • Table 5.7: Features Required for Safe and Effective Meters for Hospital Settings
  • Table 5.8: Key Features Considered for Reagent Test Strips
  • Table 5.9: Differences between Laboratory Instruments for Glucose Analysis and Hand-Held Blood Glucose Meters
  • Table 5.10: Relationship of A1c to Average Whole Blood and Plasma Glucose Levels
  • Table 5.11: Unit Sales of Homecare Lancets in the U.S.
  • Table 5.12: Unit Sales of Homecare Lancets in the E.U.
  • Table 5.13: Dollar Sales of Homecare Lancets in the U.S.
  • Table 5.14: Dollar Sales of Homecare Lancets in the E.U.
  • Table 5.15: Unit Sales of Homecare Glucose Self-Testing Lancets in the U.S.
  • Table 5.16: Unit Sales of Homecare Glucose Self-Testing Lancets in the E.U.
  • Table 5.17: Competition in the Lancet Market Segment
  • Table 5.18: Limitations of Urine Glucose Monitoring
  • Table 5.19: Advantages of Urine Glucose Monitoring
  • Table 5.20: Blood Ketone Reading Indications
  • Table 6.1: Current Blood Glucose Self-Testing Meters: Sample Size, Test Time, and Other Features
  • Table 6.2: Point of Care Blood Glucose or Blood Gas Meters Marketed for Professional Use
  • Table 6.3: Clinical Blood Chemistry Analyzers with Glucose Assays
  • Table 6.4: Detailed Features of Selected CGM Systems Currently Available
  • Table 6.5: Non-Invasive Glucose Monitoring Systems in Development
  • Table 7.1: POC Procedural Advantages for Hospital Testing
  • Table 7.2: Financial Comparison for Moderate and Waived CLIA Labs
  • Table 8.1: Data Entry and Data Management Features to Include in Future Meters
  • Table 8.2: Leading Companies for Patient Monitoring Products
  • Table 8.3: Customized Reports Must Support CAP and JCAHO Requirements
Back to Top